lobbying_activities: 3201383
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3201383 | 1886b452-4e1e-439a-93b8-18d5c5f4dceb | Q2 | ERVIN GRAVES STRATEGY GROUP, LLC | 13836 | EMERGENT BIOSOLUTIONS INC. | 2024 | second_quarter | DIS | Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY24 and FY25; Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines; NDAA for Fiscal Year 2024 and Fiscal Year 2025 - provisions related to biological and chemical defense and access to naloxone; FAA reauthorization - increasing access to naloxone. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2024-07-18T17:55:23-04:00 |